• DOI:10.14219/JADA.ARCHIVE.2008.0017
• Corpus ID: 26838987

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

@article{Grbic2008IncidenceOO,
  title={Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.},
  author={John T Grbic and Regina Landesberg and Shou-qing Lin and Peter Mesenbrink and Ian R. Reid and Ping Chung Leung and Noem{\'i} Casas and Chris Recknor and Ye Hua and Pierre Dominique Delmas and Erik Fink Eriksen},
  journal={Journal of the American Dental Association},
  year={2008},
  volume={139 1},
  pages={
          32-40
        }
}

• J. Grbic, R. Landesberg, +8 authors E. Eriksen
• Published 2008
• Medicine
• Journal of the American Dental Association

BACKGROUND
The authors determined incidence of osteonecrosis of the jaw (ONJ) in a large, prospective three-year clinical trial of zoledronic acid in women with postmenopausal osteoporosis (PMO).

METHODS
A total of 7,714 women with PMO received intravenous zoledronic acid 5 mg or a placebo. No spontaneous reports of ONJ were received. An independent, blinded adjudication committee searched the trial's adverse event database by using 60 terms. On an ongoing basis, the committee reviewed the identified events, and it defined ONJ as exposed bone in the maxillofacial area with delayed healing for more than six weeks despite appropriate care.

RESULTS
One participant who received a placebo and one participant who received zoledronic acid experienced delayed healing associated with infection. Both conditions resolved after antibiotic therapy, débridement or both.

CONCLUSION
The occurrence of ONJ is rare in a PMO population, and delayed healing of lesions can occur with and without bisphosphonate use over three years.

CLINICAL IMPLICATIONS
The low incidence of ONJ must be assessed in the context of the clinical benefit of zoledronic acid therapy in reducing hip, vertebral and nonvertebral fractures in this at-risk population. There is no evidence to suggest that healthy patients with osteoporosis who are receiving bisphosphonates require any special treatment beyond routine dental care or to support altering standard treatment practices.